Key Takeaways
- Immutep shares experienced a dramatic 101% surge Wednesday following FDA Orphan Drug Designation approval for eftilagimod alfa (efti).
- The designation applies to soft tissue sarcoma treatment, a rare form of cancer impacting under 200,000 Americans annually.
- Advantages encompass seven-year market exclusivity rights, tax incentives, waived regulatory fees, and enhanced FDA guidance.
- Supporting evidence derives from Phase II EFTISARC-NEO clinical trial results, successfully achieving primary objectives across 38 participants.
- The development arrives after discontinuation of TACTI-004 Phase III testing, potentially extending financial sustainability through Q2 2027 and beyond.
Shares of Immutep experienced remarkable growth Wednesday, climbing more than 100% following confirmation that the U.S. Food and Drug Administration granted Orphan Drug Designation (ODD) for the company’s principal oncology candidate, eftilagimod alfa.
The Australian Securities Exchange-listed biotechnology firm witnessed its share price rocket 101.3% to reach A$0.079 throughout Wednesday’s trading session.
The regulatory designation encompasses efti’s application in treating soft tissue sarcoma (STS), representing a rare malignancy with significant unaddressed therapeutic requirements within the American healthcare landscape.
Orphan Drug Designation delivers substantial strategic advantages: enhanced regulatory consultation, qualifying tax incentives, exemption from certain administrative fees, and critically, seven years of commercial exclusivity rights upon final marketing approval.
The FDA’s determination drew upon evidence generated from the Phase II EFTISARC-NEO clinical investigation. This research examined efti administered alongside radiotherapy and Merck’s KEYTRUDA (pembrolizumab) in individuals diagnosed with resectable soft tissue sarcoma prior to surgical intervention.
Among 38 assessable participants, the investigation successfully achieved its primary efficacy measure. Data revealed a median tumour hyalinization/fibrosis proportion of 51.5%, substantially exceeding the predetermined threshold of 35% and the established historical standard of approximately 15% associated with radiotherapy monotherapy.
Findings remained consistent across various sarcoma classifications. Researchers characterized the tolerability profile as encouraging, noting zero instances of surgical postponement.
TACTI-004 Program Discontinuation
This encouraging FDA announcement follows Immutep’s recent termination of its TACTI-004 Phase III clinical program in early March. That investigation evaluated efti for first-line non-small cell lung cancer applications.
An Independent Data Monitoring Committee issued recommendations for trial cessation based on futility findings. The organization is currently executing an organized wind-down of TACTI-004 operations.
Immutep indicated that program closure should significantly extend available capital resources beyond earlier projections of Q2 2027.
Development Portfolio and Financial Position
Beyond soft tissue sarcoma and lung cancer applications, Immutep maintains five active LAG-3 therapeutic programs. Among these initiatives, IMP761 is presently undergoing Phase I evaluation targeting autoimmune condition treatments.
The organization reported a net financial loss of A$61.4 million throughout the 2025 fiscal period, representing an increase from the A$42.7 million deficit recorded in 2024.
Operating as a pre-revenue biotechnology enterprise, Immutep continues requiring supplementary capital infusions to support ongoing research and development activities.
The company sustains collaborative arrangements with prominent pharmaceutical corporations, including Merck (MSD), facilitating advancement of its therapeutic pipeline.
The EFTISARC-NEO trial evidence, which directly underpinned Wednesday’s FDA designation decision, incorporated translational research findings aligned with efti’s proposed biological mechanism — immune system activation through LAG-3 pathway engagement.
